Reprint

The Interplay of Microbiome and Immune Response in Health and Diseases

Edited by
November 2019
206 pages
  • ISBN978-3-03921-646-8 (Paperback)
  • ISBN978-3-03921-647-5 (PDF)

This book is a reprint of the Special Issue The Interplay of Microbiome and Immune Response in Health and Diseases that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

[Increasing evidence suggests that microbiota and especially the gut microbiota (the microbes inhabiting the gut including bacteria, archaea, viruses, and fungi) plays a key role in human physiology and pathology. Recent findings indicate how dysbiosis—an imbalance in the composition and organization of microbial populations—could severely impact the development of different medical conditions (from metabolic to mood disorders), providing new insights into the comprehension of diverse diseases, such as IBD, obesity, asthma, autism, stroke, diabetes, and cancer. Given that microbial cells in the gut outnumber host cells, microbiota influences human physiology both functionally and structurally. Microbial metabolites bridge various—even distant—areas of the organism by way of the immune and hormone system. For instance, it is now clear that the mutual interaction between the gastrointestinal tract and the brain (gut–brain axis), often involves gut microbiota, indicating that the crosstalk between the organism and its microbial residents represents a fundamental aspect of both the establishment and maintenance of healthy conditions. Moreover, it is crucial to recognize that beyond the intestinal tract, microbiota populates other host organs and tissues (e.g., skin and oral mucosa). We have edited this eBook with the aim of publishing manuscripts focusing on the impact of microbiota in the development of different diseases and their associated treatments.]

Format
  • Paperback
License
© 2019 by the authors; CC BY-NC-ND license
Keywords
microbiota; rheumatoid arthritis; anti-TNF-α; methotrexate; etanercept; disease activity; microbiome; health; precision medicine; genomics; bacteriocins; bacteriophages; antibiotics; gastrointestinal diseases; dysbiosis; gut barrier; gut microbiota; virus; vaginal microbiota; HIV; HPV; HSV2; cytokines; chemokines; innate immunity; adaptive immunity; microbiota; autoimmunity; etiopathogenesis; Candida albicans; 2,3-dihydroxy-4-methoxyBenzaldehyde; melanin; colitis; anaerobic bacteria; aerobic bacteria; gut microbiota; gut-liver axis; chronic liver diseases; fecal transplantation; probiotics; gut microbiota; immunological niche; dysbiosis; cancer; immune system; cutaneous immunity; microbiome; Staphylococcus spp., T cells; Staphylococcus aureus; Staphylococcus epidermis; commensals; atopic dermatitis; intravenous immunoglobulin G; colitis; dextran sulfate sodium; mice; inflammation; cytokines; Candida albicans; Escherichia coli; Enterococcus faecalis; gut microbiota; chemo free treatment; lymphoid malignancies; 16S rRNA gene; chondroitin sulfate disaccharide; co-occurrence network; global network; microbial interactions; microbiome; modularity; superoxide dismutase; gut microbiota; macrophages; TLR mimicry; immune epigenetics; metabolism; sterile inflammation; microbiota; microbiome; immunotherapy; adoptive cell transfer (ACT); CAR T-cell; TCR; TIL; checkpoint inhibitors; immuno-oncology; cancer; diet; n/a